Skip to main content

Zachary Conrad Hartman, PhD

Assistant Professor of Surgery
Assistant Professor in Pathology
Office: Research Drive, Msrbi Rm 414, Durham, NC 27710
Campus Mail: DUMC Box 2606 Med Ctr, Durham, NC 27710

My research interests encompass studies of immunity and inflammation in the context of developing and established cancers. These research interests involve studies of inflammation in the genesis and maintenance of specific cancer types (principally breast and ovarian), as well as the impact of inflammation on tumor metastasis and the tumor microenvironment.  My group is also involved in strategies to modulate the immune response to tumors, which involves the use of novel immunotherapeutic strategies and development of vaccines to specific oncogenic targets.  The major focus of my lab is in uncovering strategies to modulate tumor-derived inflammation and tumor-specific immunity that will translate into clinically efficacious therapies in patients.

Education and Training

  • Post Doctoral Fellow, Md Anderson Cancer Center, University of Texas Medical School at Houston, 2010 - 2012
  • Post-Doctoral Fellow, Duke University, 2006 - 2010
  • Ph.D., Duke University, 2006

Publications

Crosby, EJ, Wei, J, Yang, XY, Lei, G, Wang, T, Liu, CX, Agarwal, P, Korman, AJ, Morse, MA, Gouin, K, Knott, SRV, Lyerly, HK, and Hartman, ZC. "Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors (Accepted)." OncoImmunology (January 19, 2018).

Full Text

Shuptrine, CW, Ajina, R, Fertig, EJ, Jablonski, SA, Kim Lyerly, H, Hartman, ZC, and Weiner, LM. "An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection." Cancer immunology, immunotherapy : CII 66, no. 12 (December 2017): 1529-1544.

Full Text

Hartman, Z, Crosby, E, Wei, J-P, Yang, X-Y, Lei, G-J, Wang, T, Liu, C-X, Agarwal, P, Morse, M, and Lyerly, H. "Abstract P2-04-27: CTLA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer." February 15, 2017.

Full Text

Crosby, EJ, Wei, J, Yang, XY, Lei, G, Wang, T, Liu, C-X, Agarwal, P, Lyerly, HK, and Hartman, ZC. "Abstract A38: Checkpoint blockade elicits unique T cell expansion to promote tumor regression." February 2017.

Full Text

Ren, J, Gwin, WR, Zhou, X, Wang, X, Huang, H, Jiang, N, Zhou, L, Agarwal, P, Hobeika, A, Crosby, E, Hartman, ZC, Morse, MA, H Eng, K, and Lyerly, HK. "Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy." Oncoimmunology 6, no. 4 (January 2017): e1264563-.

Full Text

Osada, T, Morse, MA, Hobeika, A, Diniz, MA, Gwin, WR, Hartman, Z, Wei, J, Guo, H, Yang, X-Y, Liu, C-X, Kaneko, K, Broadwater, G, and Lyerly, HK. "Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition." Oncoimmunology 6, no. 6 (January 2017): e1315495-.

Full Text

Turpin, J, Ling, C, Crosby, EJ, Hartman, ZC, Simond, AM, Chodosh, LA, Rennhack, JP, Andrechek, ER, Ozcelik, J, Hallett, M, Mills, GB, Cardiff, RD, Gray, JW, Griffith, OL, and Muller, WJ. "The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment." Oncogene 35, no. 47 (November 2016): 6053-6064.

Full Text

Mazumdar, A, Poage, GM, Shepherd, J, Tsimelzon, A, Hartman, ZC, Den Hollander, P, Hill, J, Zhang, Y, Chang, J, Hilsenbeck, SG, Fuqua, S, Kent Osborne, C, Mills, GB, and Brown, PH. "Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion." Breast cancer research and treatment 158, no. 3 (August 2016): 441-454.

Full Text

Zhao, J, Zhao, D, Poage, GM, Mazumdar, A, Zhang, Y, Hill, JL, Hartman, ZC, Savage, MI, Mills, GB, and Brown, PH. "Death-associated protein kinase 1 promotes growth of p53-mutant cancers." The Journal of clinical investigation 125, no. 7 (July 2015): 2707-2720.

Full Text

Osada, T, Nagaoka, K, Takahara, M, Yang, XY, Liu, C-X, Guo, H, Roy Choudhury, K, Hobeika, A, Hartman, Z, Morse, MA, and Lyerly, HK. "Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors." Journal of immunotherapy (Hagerstown, Md. : 1997) 38, no. 4 (May 2015): 155-164.

Full Text

Pages